Biphasic release formulations for lipophilic drugs
CA 2093206 C · Owner: Provalis Uk Limited · Inventors: Barnwell, Stephen G.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A pharmaceutical formulation comprises: (a) a C12-C24 fatty acid, which may be saturated or mono- or poly-unsaturated, such as oleic or linoleic acid;, and, (b) a generally lipophilic pharmaceutically active substance. A portion of the C12-C24 fatty acid is formulated for nonsustained release on non-parenteral administration and a portion of the C12-C24 fatty acid and at least a portion of the pharmaceutically active substance are formulated for sustained release on non-parenteral administration. The pharmaceutically active substance may be a cardiovascular drug such as propranolol verapamil, nifedipine, diltiazem, metoprolol nicardipine or, labetolol. Such formulations promote absorbtion …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 18, 1991 and granted January 29, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 18, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 18, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.